Argenx (NASDAQ: ARGX) is a global immunology company that develops treatments for severe autoimmune diseases. The company's stock is currently trading at $987.84, giving it a market capitalization of approximately $61.43 billion. Market capitalization is the total value of all a company's shares of stock, calculated by multiplying the share price by the number of shares.
Following recent developments, analyst firm Wedbush increased its price target for Argenx to $1,150 from a previous target of $1,050. This new target, set on August 18, 2026, represents a potential upside of about 16.42% from the stock's price at the time. An upside is the potential increase in a stock's value.
This optimism is driven by positive news from the company's Phase 3 ALKIVIA clinical trial. Argenx announced successful topline results for its treatment, VYVGART Hytrulo. The trial tested the drug's effectiveness in adults with autoimmune myositis, a condition that causes chronic muscle inflammation and weakness.
The study successfully met its primary endpoint, which is the main goal a trial aims to achieve. It showed a statistically significant improvement with a p-value of 0.0011, as reported by MarketBeat. A p-value this low suggests the results are highly reliable and not simply due to chance.
As highlighted by Benzinga, these results are significant because they offer a new, targeted treatment option. This is especially important for patients with IMNM, a subtype of the disease that currently has no approved therapies. The new treatment precisely targets the specific antibodies that are key drivers of the disease.
